Epigenetic alterations in gastric carcinogenesis

Cell Research

Volumn 15, Issue 4, 2005, Pages 247-254

  Choi, In Seon ^a   Wu, Tsung Teh ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adenocarcinoma; Chronic gastritis; Dysplasia adenoma; Epigenetic alterations; Gastric carcinogenesis; Intestinal metaplasia

Indexed keywords

ADENOCARCINOMA; ANIMAL; CARCINOGEN TESTING; CPG ISLAND; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HUMAN; REVIEW; STOMACH TUMOR;

ADENOCARCINOMA; ANIMALS; CARCINOGENICITY TESTS; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; STOMACH NEOPLASMS;

EID: 24344473427     PISSN: 10010602     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cr.7290293     Document Type: Review

References (88)

1. Nardone G. Molecular basis of gastric carcinogenesis. Aliment Pharmacol Ther 2003; 17:75-81.
2. Baylin SB. Tying it all together: epigenetics, genetics, cell cycle, and cancer. Science 1997; 277:1948-9.
3. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3:415-28.
4. Takacs M, Salamon D, Myohanen S, et al. Epigenetics of latent Epstein-Barr virus genomes: high resolution methylation analysis of the bidirectional promoter region of latent membrane protein 1 and 2B genes. Biol Chem 2001; 382:699-705.
5. Tierney RJ, Kirby HE, Nagra JK, et al. Methylation of transcription factor binding sites in the Epstein-Barr virus latent cycle promoter Wp coincides with promoter down-regulation during virus-induced B-cell transformation. J Virol 2000; 74: 10468-79.
6. Robertson KD. The role of DNA methylation in modulating Epstein-Barr virus gene expression. Curr Top Microbiol Immunol 2000; 249:21-34.
7. Tao Q, Swinnen LJ, Yang J, et al. Methylation status of the Epstein-Barr virus major latent promoter C in iatrogenic B cell lymphoproliferative disease: application of PCR-based analysis. Am J Pathol 1999; 155:619-25.
8. Hagan CR, Rudin CM. Mobile genetic element activation and genotoxic cancer therapy: potential clinical implications. Am J Pharmacogenomics 2002; 2:25-35.
9. Nelson WG, De Marzo AM, Deweese TL, et al. Preneoplastic prostate lesions: an opportunity for prostate cancer prevention. Ann N Y Acad Sci 2001; 952:135-44.
10. Rideout WM III, Eggan K, Jaenisch R. Nuclear cloning and epigenetic reprogramming of the genome. Science 2001; 293:1093-8.
11. Nelson WG, De Marzo AM, DeWeese TL. The molecular pathogenesis of prostate cancer: implications for prostate cancer prevention. Urology 2001; 57 (Suppl 1):39-45.
12. Howell CY, Bestor TH, Ding F, et al. Genomic imprinting disrupted by a maternal effect mutation in the Dnmt1 gene. Cell 2001; 104:829-38.
13. El-Osta A, Wolffe AP. DNA methylation and histone deacetylation in the control of gene expression: basic biochemistry to human development and disease. Gene Expr 2000; 9:63-75.
14. Zuccotti M, Garagna S, Redi CA. Nuclear transfer, genome reprogramming and novel opportunities in cell therapy. J Endocrinol Invest 2000; 23:623-9.
15. Feinberg AP. Cancer epigenetics takes center stage. Proc Natl Acad Sci USA 2001; 98:392-4.
16. Feinberg AP. DNA methylation, genomic imprinting and cancer. Curr Top Microbiol Immunol 2000; 249:87-99.
17. Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 1999; 96:8681-6.
18. Momparler RL, Bovenzi V. DNA methylation and cancer. J Cell Physiol 2000; 183:145-154.
19. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999; 21:163-7.
20. Li E, Beard C, Jaenisch R. Role for DNA methylation in genomic imprinting. Nature 1993; 366:362-5.
21. Panning B, Jaenisch R. RNA and the epigenetic regulation of X chromosome inactivation. Cell 1998; 93:305-8.
22. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000; 16:168-74.
23. Toyota M, Issa JP. The role of DNA hypermethylation in human neoplasia. Electrophoresis 2000; 21:329-33.
24. Wajed SA, Laird PW, DeMeester TR. DNA methylation: an alternative pathway to cancer. Ann Surg 2001; 234:10-20.
25. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process-first American cancer society award lecture on cancer epidemiology and prevention. Cancer Res 1992; 52:6735-40.
26. Correa P, Shiao YH. Phenotypic and genotypic events in gastric carcinogenesis. Cancer Res 1994; 54:1941s-3s.
27. Maesawa C, Tamura G, Suzuki Y, et al. The sequential accumulation of genetic alterations characteristic of the colorectal adenoma-carcinoma sequence does not occur between gastric adenoma and adenocarcinoma. J. Pathol 1995; 176:249-58.
28. Stadtlander CT, Waterbor JW. Molecular epidemiology, pathogenesis and prevention of gastric cancer. Carcinogenesis 1999; 20:2195-208.
29. Kolodziejczyk P, Yao T, Oya M, et al. Long-term follow-up study of patients with gastric adenomas with malignant transformation An immunohistochemical and histochemical analysis. Cancer 1994; 74:2896-907.
30. Orlowska J, Jarosz D, Pachlewski J, et al. Malignant transformation of benign epitherial gastric polyps. Am J Gastroenterol 1995; 90:2152-9.
31. Kang GH, Shim YH, Jung HY, et al. CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res 2001; 61:2847-51.
32. Kang GH, Lee S, Kim JS, Jung HY. Profile of aberrant CpG island methylation along multistep gastric carcinogenesis. Lab Invest 2003; 83:519-26.
33. Baylin SB, Herman JG, Graff JR, et al. Alterations in DNA ethylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998; 72:141-96.
34. Jones PA. DNA methylation errors and cancer. Cancer Res 1996; 56:2463-7.
35. Laird PW, Jaenisch R. DNA methylation and cancer. Hum Mol Genet 1994; 3:1487-95.
36. Herman JG, Merlo A, Mao L, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995; 55:4525-30.
37. Merlo A, Herman JG, Mao L, et al. 5k CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Med 1995; 1:686-92.
38. Sakai T, Toguchida J, Ohtani N, et al. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am J Hum Genet 1991; 48:880-8.
39. Greger V, Passarge E, Hopping W, et al. Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum Genet 1989; 83:155-8.
40. Esteller M, Sparks A, Toyota M. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res 2000; 60:4366-71.
41. Esteller M, Corn PG, Baylin SB, et al. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61:3225-9.
42. Graff JR, Herman JG, Lapidus RG, et al. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 1995; 55:5195-9.
43. Kane MF, Loda M, Gaida GM, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997; 57:808-11.
44. Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 1998; 95:6870-5.
45. Esteller M, Levine R, Baylin SB, et al. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 1998; 17:2413-7.
46. Esteller M, Catasus L, Matias-Guiu X, et al. hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. Am J Pathol 1999; 155:1767-72.
47. Fleisher AS, Esteller M, Wang S, et al. Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res 1999; 59:1090-5.
48. Esteller M, Hamilton SR, Burger PC, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999; 59:793-7.
49. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 2000; 60:2368-71.
50. 6-methylguanine-DNA methyltransferase is associated with the presence of G : C to A : T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res 2001; 61:4689-92.
51. Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000; 92:564-9.
52. Toyota M, Ahuja N, Suzuki H, et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 1999; 59:5438-42.
53. Kang GH, Lee HJ, Hwang KS, et al. Aberrant CpG island hypermethylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation. Am J Pathol 2003; 163:551-6.
54. Waki T, Tamura G, Sato M, et al. Promoter methylation status of DAP-kinase and RUNX3 genes in neoplastic and non-neoplastic gastric epithelia. Cancer Sci. 2003; 94:360-4.
55. Nakagawa H, Nuovo GJ, Zervos EE, et al. Age-related hypermethylation of the 5′ region of MLH1 in normal colonic mucosa is associated with microsatellite-unstable colorectal cancer development. Cancer Res 2001; 61:6991-5.
56. Satoh A, Toyota M, Itoh F, et al. DNA methylation and histone deacetylation associated with silencing DAPkinase gene expression in colorectal and gastric cancers. Br J Cancer 2002; 86:1817-23.
57. Vertino PM, Yen RW. De novo methylation of CpG island sequences in human fibroblasts overexpressing DNA (cytosine-5-)-methyltransferase. Mol Cell Biol 1996; 16:4555-65.
58. Macleod D, Charlton J, Mullins J, et al. Sp1 sites in the mouse aprt gene promoter are required to prevent methylation of the CpG island. Genes 1994; 8:2282-92.
59. 6-methylguanine-DNA methyltransferase enhancer binding protein in DNA repair-deficient human cells. Proc Nat Acad Sci USA. 1997; 94:4348-53.
60. Mummaneni P, Yates P, Simpson J, et al. The primary function of a redundant Sp1 binding site in the mouse aprt gene promoter is to block epigenetic gene inactivation. Nucleic Acids Res 1998; 26:5163-9.
61. Liang G, Salem CE, Yu MC, et al. DNA methylation differences associated with tumor tissues identified by genome scanning analysis. Genomics 1998; 53:260-8.
62. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand 1965; 64:31-49.
63. Stadtlander CT, Waterbor JW. Molecular epidemiology, pathogenesis and prevention of gastric cancer. Carcinogenesis 1999; 20:2195-208.
64. Tahara E, Semba S, Tahara H. Molecular biological observations in gastric cancer. Semin Oncol 1996; 23:307-15.
65. Chan AO, Luk JM, Hui WM, et al. Molecular biology of gastric carcinoma: from laboratory to bedside. J Gastroenterol Hepatol 1999; 14:150-60.
66. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process - first american cancer society award lecture on cancer epidemiology and prevention. Cancer Res 1992; 52:6735-40.
67. Correa P, Shiao YH. Phenotypic and genotypic events in gastric carcinogenesis. Cancer Res 1994; 54(Suppl):1941s-3s.
68. Correa P. A human model of gastric carcinogenesis. Cancer Res 1988; 48:3554-60.
69. Solcia E, Fiocca R, Luinetti O, et al. Intestinal and diffuse gastric cancers arise in a different background of Helicobacter pylori gastritis through different gene involvement. Am J Surg Pathol 1996; 20(Suppl 1):S8-S22.
70. Horii A, Nakatsuru S, Miyoshi Y, et al. The APC gene, responsible for familial adenomatous polyposis, is mutated in human gastric cancer. Cancer Res 1992; 52:3231-3.
71. Nishimura K, Yokozaki H, Jaruma K, et al. Alternations of the APC gene in carcinoma cell lines and precancerous lesions of the stomach. Int J Oncol 1995; 7:587-92.
72. Arber N, Shapira I, Ratan J, et al. Activation of c-K-ras mutations in human gastrointestinal tumors. Gastroenterology 2000; 18:1045-50.
73. Kihana T, Tsuda H, Hirota T, et al. Point mutation of c-Ki-ras oncogene in gastric adenoma and adenocarcinoma with tubular differentiation. Jpn J Cancer Res 1991; 82:308-14.
74. Lee KH, Lee JS, Suh C, et al. Clinicopathologic significance of the K-ras gene codon 12 point mutation in stomach cancer. An analysis of 140 cases. Cancer 1995; 75:2794-801.
75. Nakatsuru S, Yanagisawa A, Furukawa Y, et al. Somatic mutations of the APC gene in precancerous lesion of the stomach. Hum Mol Genet 1993; 2:1463-5.
76. Tamura G, Maesawa C, Suzuki Y, et al. Mutations of the APC gene occur during early stages of gastric adenoma development. Cancer Res 1994; 54:1149-51.
77. Rugge M, Farinati F, Di Mario F, et al. Gastric epithelial dysplasia: a prospective multicenter follow-up study from the Interdisciplinary Group on Gastric Epithelial Dysplasia Multicenter Study. Hum Pathol 1991; 22:1002-8.
78. Rugge M, Farinati F, Baffa R, et al. Gastric epithelial dysplasia in the natural history of gastric cancer: a multicenter prospective follow-up study. Interdisciplinary Group on Gastric Epithelial Dysplasia. Gastroenterology 1994; 107:288-96.
79. Orlowska J, Jarosz D, Pachlewski J, et al. Malignant transformation of benign epithelial gastric polyps. Am J Gastroenterol 1995; 90:2152-9.
80. Kamiya T, Morishita T, Asakura H, et al. Long-term follow-up study on gastric adenoma and its relation to gastric protruded carcinoma. Cancer 1982; 50:2496-503.
81. Lee JH, Park SJ, Abraham SC, et al. Frequent CpG island methylation in precursor lesions and early gastric adenocarcinomas . Oncogene 2004; 23:4646-54.
82. To KF, Leung WK, Lee TL, et al. Promoter hypermethylation of tumor-related genes in gastric intestinal metaplasia of patients with and without gastric cancer. Int J Cancer 2002; 102:623-8.
83. Leung WK, Yu J, Ng EK, et al. Concurrent hypermethylation of multiple tumor-related genes in gastric carcinoma and adjacent normal tissues. Cancer 2001; 91:2294-301.
84. Tamura G, Yin J, Wang S, et al. E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst 2000; 92:569-73.
85. An C, Choi IS, Yao JC, et al. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res 2005; 11:656-63.
86. Etoh T, Kanai Y, Ushijima S, et al. Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. Am J Pathol 2004; 164:689-99.
87. Sun Y, Deng D, You WC, et al. Methylation of p16 CpG islands associated with malignant transformation of gastric dysplasia in a population-based study. Clin Cancer Res 2004; 10:5087-93.
88. 6-methyl guanine-DNA methyltransferase gene is associated significantly with K-ras mutation, lymph node invasion, tumor staging, and disease free survival in patients with gastric carcinoma. Cancer 2001; 92:2760-8.